Oncotide Pharmaceuticals (United States)

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

Mahnaz Janghorban, Amy Farrell, Brittany L. Allen-Petersen et al. · Proceedings of the National Academy of Sciences · 2014 · 190 citations · Full text

Medicine, Cancer Biology, Oncology +17

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Dale J. Christensen, Youwei Chen, Jessica Oddo et al. · Blood · 2011 · 128 citations · Full text

Medicine, Hematology, Oncology +12

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa et al. · Clinical Cancer Research · 2014 · 124 citations

Medicine, Oncology, Pharmacology +17

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

Amy Farrell, Brittany L. Allen-Petersen, Colin J. Daniel et al. · Molecular Cancer Research · 2014 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

Brittany L. Allen-Petersen, Tyler Risom, Zipei Feng et al. · Cancer Research · 2018 · 90 citations · Full text

Life Sciences, Cell Biology, Oncology +17